NC
HRTX icon

nVerses Capital’s Heron Therapeutics HRTX Stock Holding History

nVerses Capital’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-7,800
Closed -$27.3K – 1182
2024
Q2 		$27.3K Buy
+7,800
New +$24K 0.02% 718

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

nVerses Capital's HRTX Position: Q3 2024 in Review

nVerses Capital sold out of Heron Therapeutics (HRTX) in Q3 2024, closing a stake of 7,800 shares — an estimated $27.3K sold.

nVerses Capital first reported a position in HRTX in Q2 2024 and held it in 1 quarter. The position peaked at $27.3K in Q2 2024. 173 funds tracked by Wall St. Rank hold HRTX as of Q3 2024.

  • nVerses Capital reported no remaining Heron Therapeutics position as of Q3 2024 after selling out during the quarter.
  • nVerses Capital sold 7,800 Heron Therapeutics shares in Q3 2024, an estimated $27.3K.
  • nVerses Capital first reported a position in Heron Therapeutics in Q2 2024 and held it in 1 quarter.
  • nVerses Capital's Heron Therapeutics position peaked at $27.3K in Q2 2024.
  • 173 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.